Linked Life Data

15375521

Source:http://linkedlifedata.com/resource/pubmed/id/15375521

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2004-9-17
pubmed:abstractText
The urokinase-type plasminogen activator (uPA) system plays a central role in the blood clot dissolution and tissue plasticity. uPA is a serine protease that is also involved in the metastatic process upon activation and binding to its receptor (uPAR). Studies have shown that levels of uPA in malignant tumors are higher than in the corresponding normal tissue or in benign tumors of the same tissue. We investigated uPA and uPAR gene expression in 20 human transitional cell carcinomas (TCC) of the bladder (n=19) and the renal pelvis (n=1) in comparison with adjacent non-malignant tissues. We performed mRNA in situ hybridization (isH) and immunohistochemical staining. uPA-mRNA and uPAR-mRNA were present in 95% (19/20) and 85% (17/20) of the TCC samples, respectively and significantly higher expressed than in the adjacent normal tissue. uPA-mRNA was expressed only in malignant urothelial cells, whereas uPAR-mRNA was localized in malignant urothelial cells as well as in surrounding stromal cells. There was a statistically significant lower expression of uPA/uPAR-protein in adjacent normal tissue. Strong uPAR-protein signal intensity was related to a marked protein expression as semi-quantitatively determined by immunohistochemistry. For uPA-protein this observation was less frequent. There was a statistical trend that higher expression of uPA and uPAR corresponded with tumor stage and grade of TCC. Statistical significance was reached for uPAR-antigen compared to tumor stage (p=0.025). We conclude that higher expression of uPA and uPAR could indicate a more aggressive phenotype of TCC.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1021-335X
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
909-13
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:15375521-Aged, pubmed-meshheading:15375521-Aged, 80 and over, pubmed-meshheading:15375521-Carcinoma, Transitional Cell, pubmed-meshheading:15375521-Case-Control Studies, pubmed-meshheading:15375521-Female, pubmed-meshheading:15375521-Gene Expression Regulation, Neoplastic, pubmed-meshheading:15375521-Humans, pubmed-meshheading:15375521-Immunoenzyme Techniques, pubmed-meshheading:15375521-In Situ Hybridization, pubmed-meshheading:15375521-Kidney, pubmed-meshheading:15375521-Male, pubmed-meshheading:15375521-Middle Aged, pubmed-meshheading:15375521-Neoplasm Staging, pubmed-meshheading:15375521-Pelvis, pubmed-meshheading:15375521-RNA, Messenger, pubmed-meshheading:15375521-RNA Probes, pubmed-meshheading:15375521-Receptors, Cell Surface, pubmed-meshheading:15375521-Receptors, Urokinase Plasminogen Activator, pubmed-meshheading:15375521-Stromal Cells, pubmed-meshheading:15375521-Urinary Bladder Neoplasms, pubmed-meshheading:15375521-Urokinase-Type Plasminogen Activator, pubmed-meshheading:15375521-Urothelium
pubmed:year
2004
pubmed:articleTitle
In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
pubmed:affiliation
Department of Urology, University Hospital Charité, Humboldt University, Berlin, Germany.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't